UBS and former UBS Broker William Hobby put Claimants in Harm’s Way - Customer Claim filed by Mark Tepper law firm alleges
April 08, 2019 09:36 ET
|
Mark A. Tepper, P.A.
FT. LAUDERDALE, Fla., April 08, 2019 (GLOBE NEWSWIRE) -- The law firm of Securities Fraud Attorney Mark A. Tepper has filed claim against UBS [NYSE: UBS] on behalf of a Georgia couple who entrusted...
Eight Presentations at ASM Microbe Include Late Breaker From Cempra’s Phase 3 Fusidic Acid Study and Solithromycin Data on Gonorrhea and Otitis Media
June 02, 2017 07:15 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., June 02, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Reports First Quarter 2017 Financial Results and Provides Corporate Update
April 28, 2017 07:00 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., April 28, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Retains Morgan Stanley to Lead Review of Strategic Business Options
March 13, 2017 07:00 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., March 13, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing differentiated anti-infectives for the acute care and...
Cempra to Present at 29th Annual ROTH Conference
March 03, 2017 07:00 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., March 03, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing differentiated anti-infectives for the acute care and...
Cempra Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results
February 28, 2017 06:45 ET
|
Cempra, Inc.
—Management to host webcast and conference call today at 8:45 a.m. ET— CHAPEL HILL, N.C., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company...
Cempra’s Fusidic Acid Achieves Primary Endpoint in Phase 3 Study of ABSSSI
February 24, 2017 07:00 ET
|
Cempra, Inc.
—Fusidic acid met primary endpoint and secondary efficacy endpoints— —Fusidic acid well tolerated in the study— CHAPEL HILL, N.C., Feb. 24, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a...
Cempra to Report Fourth Quarter and Full Year 2016 Financial Results
February 14, 2017 16:15 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., Feb. 14, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
CORRECTING and REPLACING -- Cempra to Present at Upcoming Investor Conferences
February 08, 2017 09:41 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., Feb. 08, 2017 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Cempra, Inc. (Nasdaq:CEMP), the Leerink Partners conference should be noted...
Cempra to Present at Upcoming Investor Conferences
February 08, 2017 07:30 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...